is not so common.
arms).
[1] The exact mechanism of injury during ERCP is unknown, but they can be categorized as mechanical, chemical, enzymatic, and possibly thermal. [3] It seems that the ampullary edema may cause temporary outflow obstruction of pancreatic juice, and then increase ductal pressure, resulting in the occurrence of pancreatitis. [1, 4] A number of drugs have been applied for prevention or alleviation of the PEP pancreatitis. [3, 5] However, the results of these therapeutic drug interventions have been generally unsatisfactory.
A few studies referred to role of prophylactic systemic corticosteroid in the prevention of PEP because of its antiinflammatory property and autodigestion theory of PEP pancreatitis. [6, 7] On the other hand, most clinical trials did not recommend prophylactic use of corticosteroid after ERCP procedure. [7] These agents may also induce acute pancreatitis in these patients. All studies did not recommend prophylactic use of corticosteroid for ERCP. [6, 7] Numerous well described side effects of corticosteroids were described either. However, we think that these side effects will be significantly diminished after a single dose and locally injection. [7] Local injection of methyl prednisolone around the papilla may reduce papillary edema. Based on this hypothesis, in a hospital-based, prospectively randomized clinical trial study we evaluated if prophylactic local injection corticosteroids around the papilla decrease the incidence of PEP pancreatitis.
MATERIALS AND METHODS

Trial registrations and organization
This clinical trial study is registered by the Iranian Clinical Trial registration Center at Iranian ministry of health and education (Trial Number: Irct-21342). This trial was conducted as a single center trial at Al-Zahra university hospital in Isfahan, Iran. The study is financially supported by the vice chancellor of research at Isfahan University of medical sciences (research proposal number at faculty of medicine: 393937).
Objectives of our study
In our study, the main objective was to determine whether locally injection of methyl prednisolone administrated after the ERCP procedure could decrease the occurrence and severity of PEP pancreatitis. Secondary aims included the assessment of the severity of PEP pancreatitis, the duration of the hospital stay, the amylase and lipase levels measured 6 and 24 h PEP, and the in hospital mortality after ERCP.
Study design and patients
This double-blind, randomized, placebo-controlled clinical trial was done between September 2014 and February 2015. All patients, undergoing therapeutic or diagnostic ERCP in the gastrointestinal endoscopy ward of Al-Zahra Hospital, Isfahan, Iran, enrolled the study. This department is one of the recognized ERCP centers in the central part of Iran. Contributing endoscopists were highly skilled operators who had been performing ERCPs for at least 5 years.
In our study, the population of the study consisted of serially enrolled patients above 18 years scheduled to undergo ERCP. Exclusion criteria's were age lower than 18, active (<2 weeks before ERCP) or chronic pancreatitis, history of previous sphincterotomy, acute renal failure, pregnancy or refusal to give informed consent. Then, all eligible patients were invited to take part in the study and had to give written informed consent before study entry.
During ERCP, we randomly assigned the patients in blocks of 40 to undergo a locally injection of methylprednisolone acetate (prednisolone group) or a block of 91 to saline (control group) (in a 1:2 drug/placebo group ratio) around the major papilla and prospectively evaluated the occurrence of PEP pancreatitis in each groups. Deciding as using of either placebo or prednisolone was performed in the ERCP Unit, whereas gastrointestinal ward physician caring for PEP patients was unaware of assigned treatments.
All patients had fasted over night before doing ERCP. The procedures were done under local and light anesthesia with a combination of meperidine, hyoscine, midazolam, and propofol as premedications and during the procedure.
Primarily, a TRUEtome Cannulating Sphincterotome (M00545150; Autotome RX 49 Cannulating Sphincterotome; Boston, Massachusetts, USA) was used for cannulation and when this failed, a tapered catheter (M00530960; Fluoro Tip ERCP Cannula Standard Tip; Boston, Massachusetts, USA) was subsequently used with a guide wire. Placebo (1 mL of 0.9% saline solution) or methylprednisolone acetate (40 mg/1 mL Depocortin ® , injection, Iran-hormone, Tehran, Iran), were injected periampullary using after the endoscopic session around the papilla in the second part of duodenum. Using of sedatives, analgesics, and antibiotics were permitted as needed. Finally, some independent variables such as: Total number of trials for pancreatic duct injections, length of sphincterotomy, number of cannulations, common bile duct morphological appearance, diameter of the bile duct; using needle-knife sphincterotomy, possibility of pancreatic acinarization during contrast injection, and the presence of choledocolithiasis were recorded by endoscopist in the questionnaires. Then, the technical difficulty level of the procedure was applied according to the scores Schutz and Abbott.
Data were collected by means of a validated questionnaire during the procedure and before discharge.
Definition of postendoscopic retrograde cholangiopancreatography pancreatitis
In this study, we defined PEP as a combination of elevated serum amylase or lipase levels (more than a threefold increase of the normal upper limit) associated with at least two clinical symptoms (new or increased abdominal pain or tenderness, backache, nausea, and vomiting) after the procedure for 6-24 h or requiring hospital admission or prolongation of a planned admission.
The normal upper limit of serum amylase and lipase is 180 IU/L and 90 IU/L, respectively. The severity of pancreatitis was graded according to Cotton et al. classification and it was categorized according to the duration of therapeutic intervention for PEP. [8] Usually mild PEP needs hospitalization not for more than 2-3 days; moderate PEP required 4-10 days; and severe PEP necessitated more than 10 days, and probably more needed to surgical or intensive care unit treatment, or contributed to death. Serum amylase and lipase levels were measured before ERCP and at 6 h and 24 h after ERCP.
Statistical analysis
We used the Student's t-test for continuous variables and the Chi-square test for category data. Statistical significance of differences was determined by P < 0.05. Statistical analysis was performed by using SPSS software (version 19.0; SPS Inc., Chicago IL, USA).
Ethical considerations
All patients had been given a detailed session on the nature, choices, and probable consequences of the trial by a responsible physician and then before entry to this trial, give written informed consent from patient and one of his/her relatives.
RESULTS
Between August 2014 and February 2015, 149 ERCP procedures were performed in Al-Zahra hospital. A total of 126 patients were eligible for this study; 29 patients received local methylprednisolone injection at the end of ERCP procedure. The flowchart by which patients were enrolled and treated is illustrated in Figure 1 . Table 1 shows demographic data of our patients. Two groups were similar with regard to indications for ERCP and also risk factors that might increase the possibility of PEP [ Table 2 ]. No patients underwent precut sphincterotomy, pancreatic stent placement or using suppository nonsteroidal antiinflammatory drugs (NSAID) at the end of the procedure.
Serum concentration of amylase and lipase were determined at baseline, 6 and 24 h after doing ERCP. Table 3 shows the mean concentration of amylases and lipase at different times. After ERCP, hyperamylasemia was observed in 7 patients (24.4%) in the corticosteroid receiving group and 40 patients (41.1%) in the control group, although the difference was not statistically significant (P = 0.07). Increase in serum lipase concentration after ERCP was seen in 6 in the corticosteroid receiving group (20.7%) and 38 patients in the control group (39%) with no statistically significant difference (P = 0.08). Besides, there is no significant difference in the mean concentration of lipase and amylase between corticosteroid receiving group and placebo receiving group at the first, second, and third time [ Table 3 ]. The frequency of moderate to severe PEP pain was not significantly between the placebo and corticosteroid receiving group (13.7% vs. 9.3%, respectively; P = 0.8).
The occurrence of PEP pancreatitis is summarized Table 4 . In the corticosteroid receiving group, 3 patients (10.3%) developed pancreatitis; on the other hand, among Control Group, 11 patients (11.3%) developed pancreatitis. There was no significant difference (P = 0.4) in the overall incidence of PEP pancreatitis in the corticosteroid treated group when compared with control group.
DISCUSSION
The most common complication of diagnostic and therapeutic ERCP is acute pancreatitis, which occurring in 1-15% of patients.
[1] During ERCP and endoscopic sphincterotomy, the pancreas is subjected to many types of potential damage including of enzymatic, infectious, allergic, mechanical, thermal, chemical, and finally hydrostatically. All above mentioned types of injury may act separately or work together to induce postprocedure pancreatitis. [3, 9] The number of ERCP performed annually in the world has increased dramatically over the past 25 years, and PEP pancreatitis occurs commonly. [9] A number of therapeutic trials have been studied due to reduce the occurrence of PEP. Several drugs were tried to find effective in the prevention of PEP pancreatitis including NSAIDS, allopurinol, glucagon, somatostatin, calcitonin, gabexate mesilate, and corticosteroid [3] [4] [5] [6] 8] but most have been disappointing. [2, 9] Since the year of 1994, corticosteroids was proposed to use as prophylactic agents for PEP because of its anti-inflammatory property. [6] Hypothetically, local injection of corticosteroid may decrease the severity of inflammation in the papillary area so it may diminish edema and subsequently lower the pancreatic ductal outflow obstruction. Our study was performed to assess the effect of locally periampullary injection of methylprednisolone after the ERCP procedure could decrease the incidence and severity of PEP pancreatitis. However, we found no significant difference in PEP rates and also severity between the corticosteroid and placebo groups. The mean increase in serum amylase and amylase level in pancreatitis patients and the frequency of abdominal pain were not significantly higher in the placebo group.
Besides, there were no cases of severe PEP pancreatitis in either group. To our knowledge, in spite of negative results, our study represents the first to evaluate the prophylactic role of local injection of corticosteroid in prevention of patients after ERCP. Several explanations are possible for this nonsignificant relation. First, the dose of corticosteroid is not sufficient for PEP prevention and the second is the noninflammatory cause of PEP. However, there are several limitations to the present article. Small number of cases included the study was the main, so we could able to analyzed the role of ERCP indications separately. It is also important to emphasize that there is currently no method to quantify the risk of developing PEP based on known demographic, clinical, and procedural risk factors. [9] 
CONCLUSION
In conclusion, the present study did not show any statistically significant benefit of prophylactic corticosteroid use for prevention of PEP. Therefore, the use of corticosteroids in the prophylaxis of PEP is not recommended.
